Cancer immunotherapy company Compugen Ltd (NASDAQ:CGEN) disclosed on Monday that it recorded a net loss of USD8.4m (USD0.14 per basic and diluted share) for the first quarter ended 31 March 2019.
This marks a decline in earnings when compared with a net income of USD0.1m (USD0.0 per basic and diluted share) in the comparable period of 2018.
Revenues of USD0 were generated for the first quarter of 2019, down over USD10m in the comparable period of 2018. The revenues for the first quarter of 2018 reflect the upfront payment of USD10m from the license agreement with MedImmune/AstraZeneca.
R&D expenses of USD6.3m were recorded for the first quarter ended 31 March 2019, from R&D of USD7.1m for the comparable period in 2018. The decrease in R&D expenses is attributed to the cost reduction measures announced during the first quarter of 2019. Further reduction in expenses will be reflected over the course of 2019.
AdaptHealth plans to close acquisition of PCS business in December 2019
Quest Diagnostics announces quarterly cash dividend
Moberg Pharma posts profit of SEK32.7m in Q1 2019
RaySearch announces EUR1.5m order for RayStation from SPHIC in Shanghai
Xbrane Biopharma swings to loss in Q3 2019
Sinovac Biotech Ltd posts net income of USD6.3m for Q3 2019
Titan Pharmaceuticals announces Q3 2019 financial results
Veloxis Pharmaceuticals swings to profit in first nine months of 2019
Mesa Labs closes acquisition of Gyros Protein Technologies for cash consideration of USD180m
UnitedHealth Group to pay dividend to holders of record as of 9 December 2019
KORU Medical Systems achieves higher USD0.02 per diluted share for Q3 2019
Jazz Pharmaceuticals reports Q3 2019 financial results
AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia for upfront USD178m